Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Open in Screener

IPSC

Century Therapeutics Inc

Feb 06 • 04:00PM ET

0.7629

Dollar change -0.0332
Percentage change -4.17	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP EDIT NTLA BEAM DNLI ARCT SGMO VERV CARR ZNTL

| Held by: VTI IWM VXF IWN VTWO SCHA IWC SCHB VTWV RSSL

Index	RUT	P/E	-	EPS (ttm)	-1.86	Insider Own	59.06%	Shs Outstand	84.76M	Perf Week	-10.25%
Market Cap	64.87M	Forward P/E	-	EPS next Y	-1.76	Insider Trans	0.00%	Shs Float	34.81M	Perf Month	-27.34%
Income	-129.89M	PEG	-	EPS next Q	-0.41	Inst Own	31.01%	Short Float	8.69%	Perf Quarter	-39.45%
Sales	2.69M	P/S	24.11	EPS this Y	30.65%	Inst Trans	26.72%	Short Ratio	4.91	Perf Half Y	-57.38%
Book/sh	2.31	P/B	0.33	EPS next Y	-10.52%	ROA	-33.04%	Short Interest	3.02M	Perf Year	-81.12%
Cash/sh	2.33	P/C	0.33	EPS next 5Y	13.21%	ROE	-62.61%	52W Range	0.75 - 5.51	Perf YTD	-24.47%
Dividend Est.	-	P/FCF	-	EPS past 5Y	15.24%	ROI	-52.69%	52W High	-86.15%	Beta	1.73
Dividend TTM	-	Quick Ratio	10.39	Sales past 5Y	-14.25%	Gross Margin	-404.17%	52W Low	1.22%	ATR (14)	0.08
Dividend Ex-Date	-	Current Ratio	10.39	EPS Y/Y TTM	15.15%	Oper. Margin	-4937.84%	RSI (14)	28.10	Volatility	8.92% 8.92%
Employees	165	Debt/Eq	0.28	Sales Y/Y TTM	7.92%	Profit Margin	-4837.73%	Recom	1.25	Target Price	7.57
Option/Short	Yes / Yes	LT Debt/Eq	0.26	EPS Q/Q	33.03%	Payout	-	Rel Volume	0.80	Prev Close	0.80
Sales Surprise	79.77%	EPS Surprise	17.91%	Sales Q/Q	434.46%	Earnings	Nov 05 BMO	Avg Volume	616.23K	Price	0.76
SMA20	-13.60%	SMA50	-30.85%	SMA200	-59.79%	Trades		Volume	495,921	Change	-4.17%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-08-24	Initiated	Rodman & Renshaw	Buy	$6
Aug-28-23	Downgrade	JP Morgan	Overweight → Neutral	$28 → $5
Dec-27-22	Initiated	Chardan Capital Markets	Buy	$19
Oct-31-22	Initiated	Guggenheim	Buy	$15
Oct-10-22	Initiated	Canaccord Genuity	Buy	$28
May-23-22	Initiated	H.C. Wainwright	Buy	$27
May-12-22	Initiated	William Blair	Mkt Perform
Jul-13-21	Initiated	Piper Sandler	Overweight	$38
Jul-13-21	Initiated	JP Morgan	Overweight	$40
Jul-13-21	Initiated	BofA Securities	Buy	$34

Jan-21-25 07:00AM	Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders (GlobeNewswire)
Nov-26-24 07:00AM	Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-08-24 12:00PM	What Makes Century Therapeutics (IPSC) a New Buy Stock (Zacks)
Nov-05-24 10:15AM	Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +5.56%
09:05AM	Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
09:00AM	Loading…
09:00AM	Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Nov-04-24 07:00AM	Century Therapeutics to Present at Guggenheim's Inaugural Healthcare Innovation Conference (GlobeNewswire)
Sep-26-24 07:00AM	Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer (GlobeNewswire)
Aug-08-24 08:50AM	Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-09-24 12:00PM	Century Therapeutics (IPSC) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Jun-03-24 07:00AM	Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting (GlobeNewswire)
May-10-24 03:35PM	Century Therapeutics Inc (IPSC) Q1 2024 Earnings: Aligns with EPS Projections Amid Strategic ... (GuruFocus.com)
07:00AM	Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting (GlobeNewswire)
May-09-24 01:54PM	IPSC Stock Earnings: Century Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:40AM	Loading…
08:40AM	Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-23-24 07:00AM	Century Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit (GlobeNewswire)
Apr-11-24 08:25AM	Century buys a startup, raises funding in cell therapy expansion (BioPharma Dive) +7.14%
07:00AM	Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics (GlobeNewswire)
Apr-08-24 04:05PM	Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +6.08%
Mar-25-24 07:00AM	Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors (GlobeNewswire) -9.48%
Mar-19-24 07:00AM	Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference (GlobeNewswire)
Mar-14-24 01:52PM	IPSC Stock Earnings: Century Therapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) -7.20%
07:30AM	Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-08-24 11:55PM	Century Therapeutics Inc (IPSC) COO Adrienne Farid Sells 53,515 Shares (GuruFocus.com)
Mar-07-24 09:55AM	How Much Upside is Left in Century Therapeutics, Inc. (IPSC)? Wall Street Analysts Think 193.4% (Zacks) +6.30%
Mar-05-24 06:03PM	Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +17.65%
Feb-01-24 07:00AM	Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Dec-09-23 12:00PM	Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion Edits (GlobeNewswire)
11:01AM	Loading…
Dec-07-23 11:01AM	Century (IPSC) Up 36% on FDA Nod to Begin Phase I Lupus Study (Zacks) +8.37%
Dec-06-23 07:30AM	Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus (GlobeNewswire) +36.08%
07:30AM	Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus (GlobeNewswire)
Dec-05-23 08:55AM	Penny Stock Jackpots: 3 High-Stakes Picks With 10-Bagger Potential (InvestorPlace)
Nov-21-23 07:00AM	Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Nov-14-23 03:58PM	FMR LLC Adjusts Position in Century Therapeutics Inc (GuruFocus.com)
Nov-09-23 08:29AM	Century Therapeutics Inc (IPSC) Reports Q3 2023 Financial Results (GuruFocus.com) -13.13%
07:01AM	Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
07:00AM	Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer (GlobeNewswire)
07:00AM	Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases (GlobeNewswire)
Nov-02-23 09:00AM	Century Therapeutics to Present Initial Clinical Data Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion Edits at the 65th ASH Annual Meeting and Exposition (GlobeNewswire)
Sep-26-23 07:00AM	Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference (GlobeNewswire)
Aug-09-23 08:50AM	Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:30AM	Century Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-01-23 06:48AM	Century Therapeutics (NASDAQ:IPSC) shareholders have endured a 71% loss from investing in the stock a year ago (Simply Wall St.)
May-12-23 06:11AM	Century Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
May-11-23 08:55AM	Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-17-23 07:00AM	Century Therapeutics to Present at Chardans 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit (GlobeNewswire)
Apr-12-23 08:30AM	Century Therapeutics Announces Leadership Changes (GlobeNewswire) -7.91%
Mar-16-23 08:55AM	Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:30AM	Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-15-23 04:01PM	Century Therapeutics to Present at the AACR Annual Meeting 2023 (GlobeNewswire)
Feb-21-23 07:00AM	Century Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-08-23 07:30AM	Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas (GlobeNewswire)
Feb-01-23 07:00AM	Century Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-17-23 09:35AM	After Plunging -29.84% in 4 Weeks, Here's Why the Trend Might Reverse for Century Therapeutics, Inc. (IPSC) (Zacks) -7.36%
Jan-09-23 10:46AM	Century Therapeutics becomes latest life sciences company to enact layoffs, narrow focus (American City Business Journals)
Jan-06-23 08:23AM	Century Therapeutics Announces Internal Portfolio Prioritization, Analyst Views It As Incrementally Positive (Benzinga)
Jan-05-23 04:01PM	Century Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026 (GlobeNewswire)
Jan-04-23 07:00AM	Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-08-22 10:02AM	Further weakness as Century Therapeutics (NASDAQ:IPSC) drops 12% this week, taking one-year losses to 39% (Simply Wall St.)
Nov-22-22 07:00AM	Century Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire) +5.24%
Nov-11-22 07:00AM	Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates (GlobeNewswire) -5.01%
Nov-10-22 08:45AM	Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +15.11%
07:30AM	Century Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-02-22 07:05AM	Century Therapeutics to Host Virtual Research and Development Day on November 11, 2022 (GlobeNewswire)
Oct-05-22 04:05PM	Century Therapeutics to Present at the SITC 37th Annual Meeting (GlobeNewswire)
Oct-03-22 07:00AM	Century Therapeutics Announces Appointment of Daphne Quimi and Timothy Walbert to its Board of Directors (GlobeNewswire)
Sep-26-22 07:00AM	Century Therapeutics to Present at Chardans 6th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-06-22 07:00AM	Century Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-25-22 07:30AM	Century Therapeutics Receives Study May Proceed Notification from FDA for CNTY-101, the First Allogeneic Cell Therapy Product Candidate Engineered to Overcome Three Major Pathways of Host vs Graft Rejection (GlobeNewswire)
Aug-11-22 08:45AM	Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Century Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-07-22 01:43PM	Century Therapeutics nearly tripling planned space at One uCity Square (American City Business Journals)
Jul-01-22 09:18AM	Further weakness as Century Therapeutics (NASDAQ:IPSC) drops 13% this week, taking one-year losses to 71% (Simply Wall St.)
Jun-24-22 04:30PM	Century Therapeutics Announces Its Addition to the Russell Microcap® Index (GlobeNewswire) -6.39% -8.37%
Jun-21-22 04:30PM	Century Therapeutics to Present at the LifeSci Partners 2nd Annual Genetic Medicines Symposium (GlobeNewswire) +5.60%
Jun-06-22 07:30AM	Century Therapeutics to Host Virtual Research and Development Day on June 13, 2022 (GlobeNewswire)
May-20-22 03:04PM	Pennsylvania Biotech Center's economic impact grows to $7B as it expands in Bucks County, report finds (American City Business Journals)
May-16-22 07:30AM	Century Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire) +9.79%
May-03-22 04:30PM	Century Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
May-02-22 04:30PM	Century Therapeutics to Present at the ASGCT 25th Annual Meeting (GlobeNewswire)
Apr-18-22 04:30PM	Century Therapeutics to Present at the Chardan Genetic Medicines and Cell Therapy Manufacturing Summit (GlobeNewswire)
Apr-06-22 04:30PM	Century Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-23-22 04:30PM	Century Therapeutics to Present at the H.C. Wainwright Gene Therapy and Gene Editing Conference (GlobeNewswire) +5.97%
Mar-17-22 07:30AM	Century Therapeutics Reports Fourth Quarter and Year-end 2021 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-09-22 04:05PM	Century Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire)
Jan-22-22 11:29AM	What's Behind Bristol Myers Squibb's Latest Partnership? (Motley Fool)
Jan-14-22 06:50AM	Inside the deal: Why Century Therapeutics picked Bristol Myers Squibb for its first Big Pharma mega-deal (American City Business Journals)
Jan-10-22 12:27PM	Century Therapeutics shares soar on potential multibillion-dollar deal with Bristol Myers Squibb (American City Business Journals) +14.52%
11:12AM	Century Therapeutics Rallies On Bristol Myers Squibb Strategic Collaboration (Investing.com)
08:08AM	Bristol Myers, Century Therapeutics Ink Pact For iPSC-Derived Allogeneic Cell Therapies (Benzinga)
06:59AM	Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies (GlobeNewswire)
Jan-04-22 04:30PM	Century Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.24%
Dec-17-21 07:00AM	Century Therapeutics Added to the NASDAQ Biotechnology Index (GlobeNewswire) +8.91%
Dec-16-21 06:30AM	Century Therapeutics Announces Presentation of Data at the 63rd American Society of Hematology Annual Meeting and Provides Pipeline Updates (GlobeNewswire)
Nov-22-21 08:00AM	Century Therapeutics to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference (GlobeNewswire) -17.56%
Nov-10-21 07:30AM	Century Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-04-21 09:00AM	Century Therapeutics to Present at the 63rd American Society of Hematology Annual Meeting and Host Virtual Research & Development Update (GlobeNewswire)

Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It focuses on harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Farid Adrienne	Chief Operations Officer	Feb 03 '25	Sale	0.78	1,054	822	134,076	Feb 05 05:31 PM
Carr Douglas	SVP Finance & Operations	Feb 03 '25	Sale	0.78	351	274	316,796	Feb 05 05:30 PM
Farid Adrienne	Officer	Feb 03 '25	Proposed Sale	0.78	1,054	823		Feb 03 03:13 PM
Farid Adrienne	Chief Operations Officer	Nov 04 '24	Sale	1.23	1,033	1,267	135,130	Nov 05 04:59 PM
Carr Douglas	SVP Finance & Operations	Nov 04 '24	Sale	1.23	283	347	317,147	Nov 05 04:59 PM
Farid Adrienne	Officer	Nov 04 '24	Proposed Sale	1.23	1,033	1,268		Nov 04 03:52 PM
Quimi Daphne	Director	Sep 12 '24	Buy	1.53	5,000	7,657	5,000	Sep 16 04:18 PM
Farid Adrienne	Chief Operations Officer	Aug 05 '24	Sale	1.83	1,073	1,960	136,163	Aug 07 04:06 PM
Carr Douglas	SVP Finance & Operations	Aug 05 '24	Sale	1.83	289	528	334,041	Aug 07 04:06 PM
Farid Adrienne	Officer	Aug 05 '24	Proposed Sale	1.83	1,073	1,960		Aug 05 03:06 PM
Russotti Gregory	See Remarks	Jul 26 '24	Sale	2.50	586	1,465	274,933	Jul 31 09:08 AM
Russotti Gregory	Officer	Jul 26 '24	Proposed Sale	2.50	586	1,465		Jul 26 05:03 PM
Russotti Gregory	See Remarks	Jul 24 '24	Sale	2.52	1,600	4,029	275,519	Jul 25 05:04 PM
Russotti Gregory	See Remarks	Jul 23 '24	Sale	2.50	200	500	277,119	Jul 25 05:04 PM
Russotti Gregory	See Remarks	Jun 20 '24	Sale	2.84	5,000	14,178	277,319	Jun 24 04:49 PM
Russotti Gregory	See Remarks	Jun 05 '24	Sale	3.00	5,000	14,989	282,319	Jun 06 04:53 PM
Russotti Gregory	See Remarks	May 20 '24	Sale	3.00	5,000	14,978	287,319	May 21 04:09 PM
Russotti Gregory	See Remarks	May 06 '24	Sale	3.12	5,000	15,619	292,319	May 07 05:13 PM
Carr Douglas	SVP Finance & Operations	May 03 '24	Sale	3.11	257	798	317,323	May 07 05:13 PM
Farid Adrienne	Chief Operations Officer	May 03 '24	Sale	3.11	913	2,836	137,236	May 07 05:13 PM
Russotti Gregory	See Remarks	Apr 22 '24	Sale	3.10	5,000	15,490	297,319	Apr 24 04:17 PM
Farid Adrienne	Chief Operations Officer	Mar 06 '24	Option Exercise	1.03	30,684	31,605	144,833	Mar 08 06:29 PM
Farid Adrienne	Chief Operations Officer	Mar 07 '24	Option Exercise	1.03	22,831	23,516	136,980	Mar 08 06:29 PM
Farid Adrienne	Chief Operations Officer	Mar 06 '24	Sale	4.96	30,684	152,340	114,149	Mar 08 06:29 PM
Farid Adrienne	Chief Operations Officer	Mar 07 '24	Sale	5.14	22,831	117,342	114,149	Mar 08 06:29 PM
Farid Adrienne	Chief Operations Officer	Feb 16 '24	Option Exercise	1.03	485	500	114,634	Feb 21 04:10 PM
Farid Adrienne	Chief Operations Officer	Feb 16 '24	Sale	4.86	485	2,358	114,149	Feb 21 04:10 PM

Dollar change +0.06
Percentage change 1.63	%

AMLX Amylyx Pharmaceuticals Inc daily Stock Chart

Peers: BIIB VRTX BMRN ALNY SRPT NBIX ACAD SAGE RARE CYTK

| Held by: VTI VXF IBB SMLF SCHA VHT IWC AVSC SBIO SCHB

Index	-	P/E	-	EPS (ttm)	-3.82	Insider Own	36.60%	Shs Outstand	68.55M	Perf Week	6.84%
Market Cap	321.34M	Forward P/E	-	EPS next Y	-1.66	Insider Trans	0.27%	Shs Float	43.46M	Perf Month	-4.34%
Income	-259.47M	PEG	-	EPS next Q	-0.52	Inst Own	66.52%	Short Float	5.71%	Perf Quarter	-34.21%
Sales	196.49M	P/S	1.64	EPS this Y	-718.93%	Inst Trans	6.23%	Short Ratio	2.34	Perf Half Y	90.36%
Book/sh	2.86	P/B	1.31	EPS next Y	61.74%	ROA	-72.35%	Short Interest	2.48M	Perf Year	-75.49%
Cash/sh	2.74	P/C	1.37	EPS next 5Y	-	ROE	-84.43%	52W Range	1.58 - 19.95	Perf YTD	-0.79%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-131.84%	52W High	-81.20%	Beta	-0.54
Dividend TTM	-	Quick Ratio	4.55	Sales past 5Y	2300.59%	Gross Margin	31.27%	52W Low	138.10%	ATR (14)	0.27
Dividend Ex-Date	Mar 28, 2018	Current Ratio	4.55	EPS Y/Y TTM	-42511.11%	Oper. Margin	-108.45%	RSI (14)	51.13	Volatility	7.61% 7.83%
Employees	384	Debt/Eq	0.01	Sales Y/Y TTM	-33.22%	Profit Margin	-132.05%	Recom	1.75	Target Price	9.25
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-456.38%	Payout	0.00%	Rel Volume	0.77	Prev Close	3.69
Sales Surprise	-	EPS Surprise	-51.99%	Sales Q/Q	-99.59%	Earnings	Nov 07 BMO	Avg Volume	1.06M	Price	3.75
SMA20	6.87%	SMA50	-9.10%	SMA200	21.40%	Trades		Volume	815,462	Change	1.63%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-18-24	Upgrade	Robert W. Baird	Neutral → Outperform	$3 → $11
Oct-23-24	Upgrade	BofA Securities	Neutral → Buy	$4.20 → $10
Mar-18-24	Downgrade	Mizuho	Buy → Neutral	$32 → $4
Mar-11-24	Downgrade	Robert W. Baird	Outperform → Neutral	$37 → $4
Mar-11-24	Downgrade	Leerink Partners	Outperform → Market Perform	$27 → $4
Mar-08-24	Downgrade	Goldman	Buy → Neutral
Mar-08-24	Downgrade	Evercore ISI	Outperform → In-line
Jan-03-24	Initiated	Robert W. Baird	Outperform	$37
Dec-12-23	Initiated	Deutsche Bank	Buy	$36
Jul-24-23	Upgrade	Goldman	Neutral → Buy	$45 → $49
Mar-31-23	Initiated	Mizuho	Buy	$52
Jan-05-23	Initiated	BofA Securities	Buy	$50
May-25-22	Initiated	Citigroup	Buy	$21
Apr-01-22	Downgrade	Goldman	Buy → Neutral	$36 → $10

Show Previous Ratings

Jan-31-25 12:00PM	Amylyx Pharmaceuticals (AMLX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Jan-22-25 05:00AM	Intellia makes progress on HAE study; 2 more China drug deals (BioPharma Dive)
Jan-21-25 09:00AM	Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis (Business Wire)
Jan-10-25 08:26AM	Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock (Business Wire) -7.16%
Jan-09-25 07:30PM	Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock (Business Wire)
09:00AM	Loading…
Jan-06-25 09:00AM	Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer (Business Wire) -5.54%
Dec-30-24 02:52PM	Why Is Amylyx Pharmaceuticals (AMLX) Among the Best Biotech Penny Stocks to Invest in Now? (Insider Monkey)
Dec-05-24 07:35AM	Amylyx announces design of LUCIDITY clinical trial (TipRanks) -5.51%
Dec-04-24 07:30AM	Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia (Business Wire)
Nov-27-24 09:00AM	Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference (Business Wire) +5.32%
Nov-08-24 02:11AM	Amylyx Pharmaceuticals Inc (AMLX) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
01:33AM	Q3 2024 Amylyx Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-07-24 07:00AM	Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results (Business Wire) +5.14%
Nov-04-24 09:00AM	Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024 (Business Wire)
Oct-25-24 09:05PM	Perceptive Advisors LLC's Strategic Acquisition in Amylyx Pharmaceuticals Inc (GuruFocus.com) +8.37%
11:12AM	Loading…
Oct-19-24 11:12AM	Amylyx Pharmaceuticals (AMLX): Leading Nano Cap in Neurodegenerative Disease Treatments (Insider Monkey)
Oct-18-24 07:34AM	Amylyxs AMX0035 shows promise in Phase II Wolfram syndrome trial (Clinical Trials Arena) +21.94%
07:26AM	Why Amylyx Pharmaceuticals Stock Was So Healthy This Week (Motley Fool)
07:04AM	PTC rebuffed again by EMA; Novartis licenses China-based biotechs cancer drug (BioPharma Dive)
Oct-17-24 09:00AM	Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome (Business Wire)
Oct-15-24 09:00AM	Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024 (Business Wire) +10.06%
Oct-09-24 05:32PM	Amylyx Pharmaceuticals Inc (AMLX) Q2 2024 Earnings Call Highlights: Strategic Pipeline ... (GuruFocus.com)
Sep-09-24 07:17PM	Director Karen Firestone Acquires 50,000 Shares of Amylyx Pharmaceuticals Inc (AMLX) (GuruFocus.com) +6.33% +5.56%
Sep-06-24 01:49AM	Director MILNE GEORGE M JR Acquires 100,000 Shares of Amylyx Pharmaceuticals Inc (AMLX) (GuruFocus.com) +7.73%
Aug-28-24 08:30AM	Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-12-24 09:00AM	Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer's Disease Pathology and Neurodegeneration (Business Wire)
Aug-08-24 07:00AM	Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results (Business Wire)
Aug-05-24 09:00AM	Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024 (Business Wire)
04:32AM	EC grants orphan drug status for Amylyxs Wolfram treatment (Pharmaceutical Technology)
Aug-02-24 09:00AM	Amylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram Syndrome (Business Wire)
10:53AM	Loading…
Jul-10-24 10:53AM	Amylyx to rebuild pipeline with $35m Phase III ready GLP-1RA acquisition (Clinical Trials Arena) +25.45%
07:00AM	Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation (Business Wire)
03:00AM	Amylyx, with GLP-1 buy, doubles down on blood sugar drugs (BioPharma Dive)
Jul-09-24 04:01PM	Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide (Business Wire)
Jun-28-24 11:02AM	Amylyx ventures into metabolic diseases market with $35.1m deal (Pharmaceutical Technology)
Jun-04-24 09:00AM	Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
May-14-24 07:25AM	Mizuho Cuts Price Target on Amylyx Pharmaceuticals to $3 From $4, Keeps Neutral Rating (MT Newswires)
May-10-24 03:54PM	Amylyx Pharmaceuticals Reports Q1 2024 Financial Results (GuruFocus.com) -7.14%
12:47PM	Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 08:15AM	Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results (Business Wire)
May-08-24 09:00AM	Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference (Business Wire)
May-02-24 09:00AM	Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024 (Business Wire)
Apr-30-24 12:02PM	Trials to watch: Four ALS drugs to keep an eye on (Clinical Trials Arena)
Apr-10-24 03:14PM	Amylyx Pharmaceuticals' Investigational Drug Shows Improved Pancreatic Function In Patients With Inherited Disorder (Benzinga) -7.87%
09:00AM	Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome (Business Wire)
Apr-08-24 09:00AM	Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024 (Business Wire)
Apr-04-24 01:20PM	Amylyx (AMLX) Withdraws ALS Drug, Cuts Workforce by 70% (Zacks)
10:05AM	ALS drug will be pulled from US market after study showed patients didn't benefit (Associated Press Finance)
07:52AM	UPDATE 1-Amylyx Pharma to remove ALS drug from US, Canada markets (Reuters)
07:43AM	Amylyx Is Cutting 70% of Its Workforce and Pulling ALS Drug From the Market (Barrons.com)
07:07AM	Amylyx Pharmaceuticals to remove ALS drug from US, Canada markets (Reuters)
07:00AM	Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO/ALBRIOZA from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy (Business Wire)
06:09AM	Amylyx to pull ALS drug from market in rare move (BioPharma Dive)
Apr-03-24 05:45AM	Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX (PR Newswire)
Apr-01-24 07:30PM	Amylyx Pharmaceuticals Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information (GlobeNewswire)
Mar-27-24 07:36AM	European study finds popular ALS drug ineffective (BioPharma Dive) +5.11%
Mar-25-24 02:33PM	Investors Sue Amylyx Pharmaceuticals (AMLX) After Analyst Questions RELYVRIO Data Hagens Berman (GlobeNewswire)
Mar-14-24 06:49PM	3 Pharma Stocks to Sell in March Before They Crash & Burn (InvestorPlace) -7.85%
09:00AM	Amylyx Pharmaceuticals Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of Directors (Business Wire)
Mar-13-24 10:00AM	SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx (PR Newswire)
09:03AM	Analysts on Wall Street Lower Ratings for These 10 Stocks (Insider Monkey)
Mar-12-24 07:55AM	After surprise trial failure, ALS doctors brace for one less treatment option (BioPharma Dive) -9.47%
Mar-11-24 12:34PM	Amylyx's (AMLX) ALS Drug Fails Pivotal Study, Stock Down 82% (Zacks) +13.10%
07:45AM	Amylyx CEOs look for a path forward following major setback (BioPharma Dive)
Mar-10-24 08:00AM	Wall Street Predicted a Blockbuster. Now the Drug May Be Withdrawn. (The Wall Street Journal)
Mar-08-24 06:27PM	Lost Money in Amylyx Pharmaceuticals, Inc.? Gibbs Law Group Investigates Potential Securities Law Violations (Business Wire) -82.29% +13.10%
04:05PM	Amylyx Stock Wipes Out Nearly All Of Its Value, Crashing 82%, After Pivotal ALS Drug Failure (Investor's Business Daily)
11:30AM	Maker of much-debated ALS drug says it may stop selling it after study showed it didn't work (Associated Press Finance)
10:20AM	Amylyxs ALS Drug Fails Trial, Raising Questions About Companys Future (Barrons.com)
10:12AM	Amylyx Stock Crashes 80% After Approved ALS Drug Fails Its Pivotal Test (Investor's Business Daily)
09:38AM	10 Biotech Stocks with Huge Potential (Insider Monkey)
09:26AM	Amylyx Pharmaceuticals Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information (GlobeNewswire)
07:07AM	Amylyx's ALS drug fails in late-stage confirmatory study (Reuters)
07:00AM	Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS (Business Wire)
02:05AM	Amylyx ALS drug fails crucial study, putting companys future in doubt (BioPharma Dive)
Feb-27-24 05:45AM	Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX (PR Newswire) +8.20%
Feb-26-24 11:39AM	AMLX NEWS: Johnson Fistel Encourages Amylyx Investors to Seek Counsel Before the Lead Plaintiff Deadline (GlobeNewswire)
Feb-25-24 06:30AM	7 Oversold Russell 2000 Stocks to Add to Your February Buy List (InvestorPlace)
Feb-23-24 04:05PM	Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
10:30AM	AMYLYX SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Amylyx To Contact Him Directly To Discuss Their Options (GlobeNewswire)
10:10AM	Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:00AM	AMLX Stockholders with Significant Losses Should Contact Robbins LLP for Information About Their Rights and Remedies Against Amylyx Pharmaceuticals, Inc. (Business Wire)
05:45AM	Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - AMLX (PR Newswire)
Feb-22-24 06:57PM	Investors Sue Amylyx Pharmaceuticals (AMLX) After Analyst Questions RELYVRIO Data Hagens Berman (GlobeNewswire) +21.10%
04:10PM	Amylyx Stock Rockets As ALS Drug Tacks On Another Triple-Digit Quarter (Investor's Business Daily)
08:15AM	Amylyx Pharmaceuticals, Inc. (AMLX) Misses Q4 Earnings Estimates (Zacks)
07:35AM	Amylyx Pharmaceuticals Inc (AMLX) Reports Robust Revenue Growth and Net Income for Full Year 2023 (GuruFocus.com)
07:00AM	Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-20-24 05:45AM	Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX (PR Newswire) -6.11%
Feb-19-24 12:40PM	Amylyx Pharmaceuticals (AMLX) Sued For Securities Fraud After Analyst Questions RELYVRIO Data Hagens Berman (GlobeNewswire)
Feb-15-24 04:05PM	Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024 (Business Wire)
02:13PM	Amylyx Pharmaceuticals (AMLX) Sued For Securities Fraud After Analyst Questions RELYVRIO Data Hagens Berman (GlobeNewswire)
09:00AM	Amylyx Pharmaceuticals to Present Updates on its AMX0114 and RELYVRIO Programs in ALS at the 2024 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference (Business Wire)
Feb-13-24 09:16PM	Lost Money in Amylyx Pharmaceuticals, Inc.? Gibbs Law Group Investigates Potential Securities Law Violations (Business Wire) -7.94%
12:58PM	Get Rich Quick With These 3 Biotech Stocks to Buy Now (InvestorPlace)
Feb-12-24 08:09PM	Amylyx Pharmaceuticals (AMLX) Sued For Securities Fraud After Analyst Questions RELYVRIO Data Hagens Berman (GlobeNewswire)
11:09AM	Amylyx Pharmaceuticals Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information (GlobeNewswire)
Feb-08-24 09:00AM	Amylyx Pharmaceuticals Announces Completion of Enrollment in HELIOS, a Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome (Business Wire)
Jan-26-24 03:57PM	3 Biotech Stocks with Potential for Major Medical Breakthroughs in 2024 (InvestorPlace)

Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Klee Justin B.	Co-Chief Executive Officer	Feb 05 '25	Option Exercise	1.57	36,310	57,007	3,201,243	Feb 06 08:17 PM
Mazzariello Gina	Chief Legal Officer	Feb 03 '25	Sale	3.49	3,678	12,839	139,090	Feb 05 04:58 PM
Cohen Joshua B	Co-Chief Executive Officer	Feb 03 '25	Sale	3.47	11,851	41,108	3,201,247	Feb 05 04:55 PM
Klee Justin B.	Co-Chief Executive Officer	Feb 03 '25	Sale	3.47	11,855	41,104	3,164,933	Feb 05 04:54 PM
Klee Justin B.	Co-Chief Executive Officer	Jan 06 '25	Sale	4.04	7,471	30,202	3,176,788	Jan 08 05:29 PM
Cohen Joshua B	Co-Chief Executive Officer	Jan 06 '25	Sale	4.05	7,471	30,232	3,213,098	Jan 08 05:26 PM
Bedrosian Camille L	Chief Medical Officer	Dec 02 '24	Sale	5.54	5,421	30,007	138,380	Dec 03 05:21 PM
Klee Justin B.	Co-Chief Executive Officer	Nov 04 '24	Option Exercise	1.57	63,690	99,993	3,184,259	Nov 06 07:24 PM
Klee Justin B.	Co-Chief Executive Officer	Sep 30 '24	Sale	3.20	18,589	59,429	3,120,569	Oct 02 06:53 PM
Cohen Joshua B	Co-Chief Executive Officer	Sep 30 '24	Sale	3.20	18,589	59,414	3,220,569	Oct 02 06:53 PM
Bedrosian Camille L	Chief Medical Officer	Sep 30 '24	Sale	3.20	11,442	36,559	143,801	Oct 02 06:50 PM
Mazzariello Gina	Chief Legal Officer	Sep 30 '24	Sale	3.20	8,709	27,840	142,768	Oct 02 06:48 PM
Cohen Joshua B	Co-Chief Executive Officer	Sep 23 '24	Option Exercise	1.57	1,857	2,915	3,239,158	Sep 25 05:56 PM
Cohen Joshua B	Co-Chief Executive Officer	Sep 12 '24	Option Exercise	1.57	34,449	54,085	3,237,301	Sep 16 05:39 PM
FRATES JAMES M	Chief Financial Officer	Sep 12 '24	Buy	2.53	40,000	101,368	233,464	Sep 16 05:30 PM
Firestone Karen	Director	Sep 05 '24	Buy	2.13	50,000	106,590	55,000	Sep 09 04:05 PM
MILNE GEORGE M JR	Director	Sep 03 '24	Buy	2.20	100,000	219,800	858,571	Sep 05 07:26 PM
Quimi Daphne	Director	May 14 '24	Buy	1.89	2,750	5,184	2,750	May 16 07:37 PM
Quimi Daphne	Director	May 15 '24	Buy	1.89	2,250	4,252	5,000	May 16 07:37 PM
Mazzariello Gina	Chief Legal Officer	May 15 '24	Sale	1.88	10,455	19,654	151,477	May 16 07:36 PM
Cohen Joshua B	Co-Chief Executive Officer	Mar 05 '24	Sale	18.73	4,135	77,440	3,023,002	Mar 07 04:05 PM
Klee Justin B.	Co-Chief Executive Officer	Mar 05 '24	Sale	18.73	4,135	77,440	2,959,308	Mar 07 04:05 PM
FRATES JAMES M	Chief Financial Officer	Mar 05 '24	Sale	18.73	1,792	33,560	134,784	Mar 07 04:05 PM
Mazzariello Gina	Chief Legal Officer	Mar 05 '24	Sale	18.73	1,540	28,841	81,372	Mar 07 04:05 PM
Mazzariello Gina	Chief Legal Officer	Feb 23 '24	Sale	18.76	2,838	53,231	46,245	Feb 27 05:59 PM

IPSC

Century Therapeutics Inc

AMLX

Amylyx Pharmaceuticals Inc

Upgrade your FINVIZ experience